These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1155 related articles for article (PubMed ID: 2305835)
1. ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies. O'Hara CJ; Corson JM; Pinkus GS; Stahel RA Am J Pathol; 1990 Feb; 136(2):421-8. PubMed ID: 2305835 [TBL] [Abstract][Full Text] [Related]
2. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma. Delahaye M; Hoogsteden HC; Van der Kwast TH J Pathol; 1991 Oct; 165(2):137-43. PubMed ID: 1744800 [TBL] [Abstract][Full Text] [Related]
3. Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12. Lee I; Radosevich JA; Chejfec G; Ma YX; Warren WH; Rosen ST; Gould VE Am J Pathol; 1986 Jun; 123(3):497-507. PubMed ID: 3717302 [TBL] [Abstract][Full Text] [Related]
4. Differential diagnosis between mesotheliomas and metastatic adenocarcinomas using monoclonal antibodies against gastrointestinal carcinoma antigen and stage-specific embryonic antigen. Ernst CS; Atkinson B; Chianese D; Peters J; Perry M; Herlyn M; Koprowski H Appl Pathol; 1986; 4(3):115-24. PubMed ID: 2885017 [TBL] [Abstract][Full Text] [Related]
5. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma. Ordóñez NG Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877 [TBL] [Abstract][Full Text] [Related]
6. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Zhu W; Michael CW Diagn Cytopathol; 2007 Jun; 35(6):370-5. PubMed ID: 17497661 [TBL] [Abstract][Full Text] [Related]
7. Use of monoclonal antibodies to keratin 7 in the differential diagnosis of adenocarcinomas. Ramaekers F; van Niekerk C; Poels L; Schaafsma E; Huijsmans A; Robben H; Schaart G; Vooijs P Am J Pathol; 1990 Mar; 136(3):641-55. PubMed ID: 1690512 [TBL] [Abstract][Full Text] [Related]
9. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Comin CE; Novelli L; Boddi V; Paglierani M; Dini S Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372 [TBL] [Abstract][Full Text] [Related]
10. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation. Soosay GN; Griffiths M; Papadaki L; Happerfield L; Bobrow L J Pathol; 1991 Apr; 163(4):299-305. PubMed ID: 2033489 [TBL] [Abstract][Full Text] [Related]
11. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations? Deniz H; Kibar Y; Güldür ME; Bakir K Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998 [TBL] [Abstract][Full Text] [Related]
12. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions. Friedman MT; Gentile P; Tarectecan A; Fuchs A Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609 [TBL] [Abstract][Full Text] [Related]
13. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen. Sheibani K; Battifora H; Burke JS Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942 [TBL] [Abstract][Full Text] [Related]
14. Malignant mesothelioma: ultrastructural distinction from adenocarcinoma. Warhol MJ; Hickey WF; Corson JM Am J Surg Pathol; 1982 Jun; 6(4):307-14. PubMed ID: 6287872 [TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies against mesothelial membrane antigen discriminate between malignant mesothelioma and lung adenocarcinoma. Stahel RA; O'Hara CJ; Waibel R; Martin A Int J Cancer; 1988 Feb; 41(2):218-23. PubMed ID: 3276635 [TBL] [Abstract][Full Text] [Related]
16. D2-40: a reliable marker in the diagnosis of pleural mesothelioma. Müller AM; Franke FE; Müller KM Pathobiology; 2006; 73(1):50-4. PubMed ID: 16785767 [TBL] [Abstract][Full Text] [Related]
17. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Ordóñez NG Mod Pathol; 1998 Oct; 11(10):929-33. PubMed ID: 9796717 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical localization of prekeratin filaments in benign and malignant cells in effusions. Comparison with intermediate filament distribution by electron microscopy. Kahn HJ; Hanna W; Yeger H; Baumal R Am J Pathol; 1982 Nov; 109(2):206-14. PubMed ID: 6182803 [TBL] [Abstract][Full Text] [Related]
19. Patterns of reactivity of four novel monoclonal antibodies (B72.3, DF3, B1.1 and B6.2) with cells in human malignant and benign effusions. Szpak CA; Johnston WW; Lottich SC; Kufe D; Thor A; Schlom J Acta Cytol; 1984; 28(4):356-67. PubMed ID: 6205527 [TBL] [Abstract][Full Text] [Related]
20. Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas. Corson JM; Pinkus GS Am J Pathol; 1982 Jul; 108(1):80-8. PubMed ID: 6178295 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]